Eurocine Vaccines AB

Equities

EUCI

SE0015382155

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
0.0354 ^SEK	-6.84%		-11.50%	-23.04%

30/05	Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
28/02	Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Eurocine Vaccines AB Announces Earnings Results for the Half-Year Ended December 2020

February 19, 2021 at 01:00 pm IST

Eurocine Vaccines AB (publ) announced earnings results for the half-year ended December 2020. Loss after tax during the first half year amounted to SEK 7.6 million against SEK 4.7 million a year ago. Revenues during the half year amounted to SEK 0.4 million. Loss per share the half year SEK 0.01 against SEK 0.03 a year ago.

Latest news about Eurocine Vaccines AB

Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	30/05	CI
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	28/02	CI
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.	15/02	CI
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023	28/11	CI
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	30/23/30	CI
Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	24/23/24	CI
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA	04/23/04	MT
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023.	17/23/17	CI
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	28/23/28	CI
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA	18/23/18	MT
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia	18/23/18	CI
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022	29/22/29	CI
Eurocine Vaccines Receives Patent Coverage In South Korea For Vaccine Candidate	30/22/30	MT
Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2022	25/22/25	CI
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	25/22/25	CI
Eurocine Vaccines Down 10% On Collaboration Deal With Redbiotec For Herpes Vaccine	15/22/15	MT
Eurocine Vaccines AB Enters into Research and Collaboration Agreement with Redbiotec AG	14/22/14	CI
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	20/22/20	CI
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	16/22/16	CI
Eurocine Vaccines Resolves on Scientific Advice with Swedish Medical Products Agency ahead of Clinical Trial Application	21/21/21	CI
Eurocine's Chlamydia Vaccine Candidate Shows Effective Response In Preclinical Trial	01/21/01	MT
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2021	17/21/17	CI
Eurocine Vaccines Announces Positive Results with Endocine and A Vaccine Candidate Against Covid-19	23/21/23	CI
Eurocine Vaccines AB Announces Earnings Results for the Quarter and Full Year Ended June 30, 2021	31/21/31	CI

Chart Eurocine Vaccines AB

Duration

Period

More charts

Company Profile

Eurocine Vaccines AB is a Sweden-based clinical-stage company, which develops nasal vaccines. The Company develops vaccines up to proof of concept (clinical phase I/II) and license to partners for further development and commercialization. Also, the Company offers license partners vaccine adjuvant technologies, which are a key element of the nasal vaccines, for development in various indications. For these purposes the Companyâs uses its clinically validated technology Endocine. In addition, the Companyâs primary project is the nasal quadrivalent influenza vaccine Immunos FLU that aims for children from six month. The Company cooperates with both academic researchers and contract businesses and owns all income generated in these collaborations.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EUROCINE VACCINES AB	-23.04%	878K
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research